GLOW Dosage Chart & Schedule Guide.

No. None of the three components is approved for any indication in any country, and no regulator has ever evaluated them as a blend. In September 2023 the FDA placed BPC-157 and thymosin beta-4 fragment into Category 2 of its interim 503A bulk drug substances policy (substances judged to present significant safety risks, which compounding pharmacies could not use). FDA’s stated concerns included immunogenicity risk by certain routes and difficulty characterising the active ingredient and its peptide-related impurities. On 22 April 2026 the outside nominations were withdrawn and FDA removed the substances from Category 2, which did not move them to Category 1 and did not put them on the final 503A Bulks List. On 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend both BPC-157 and TB-500 for the 503A bulks list, overruling FDA’s own briefing staff. That is a recommendation, not a rule change: formal rulemaking still has to happen and realistically runs into 2027. Nothing sold today as "research use only" is covered by that vote.

GHK-Cu, which is 64–71% of the blend by mass. Copper complexes irritate subcutaneous tissue in a way plain peptides do not. Four things that genuinely help: reconstitute to a larger volume (5 mL instead of 3 mL halves the concentration for the same mg; just recalculate your units), let the vial come to room temperature instead of injecting it cold from the fridge, push the plunger slowly over several seconds, and use abdominal fat rather than thin-skinned areas like the upper arm. If it still welts up every time, that is an amber sign to drop a tier.

If you have a specific target, yes. Separate vials let you run BPC-157 at 250–500 mcg/day, TB-500 at 2–5 mg twice weekly, and GHK-Cu at 1–2 mg/day, each at its own conventional dose and schedule, which are genuinely different from one another. GLOW cannot do that: it locks all three to one ratio, and at any dose that gives a real TB-500 loading amount the copper overshoot is severe. GLOW’s only real advantage is one injection instead of three, and one vial instead of three. If convenience is the priority, it is a reasonable trade. If you are rehabbing a specific injury, it is not.

GHK-Cu is about 15.8% elemental copper by mass (MW ~402, copper 63.5). At 10 units off a 70 mg vial in 3 mL that is 1.67 mg GHK-Cu, so roughly 264 mcg of copper per shot, under the 900 mcg daily RDA and far under the 10 mg/day tolerable upper limit. Here is the catch: both of those figures are for dietary copper, where your gut actively regulates how much crosses over. Injected copper skips that entirely, so the oral numbers do not tell you what is safe here and no one has established a parenteral ceiling. That is the real argument for cycling and for not creeping past 20–25 units.

Do not inject it into your face, and do not use reconstituted GLOW as a mesotherapy or microneedling product; it is not formulated, buffered or tested for that, and facial injection of an unapproved copper complex risks granulomas and pigment changes. Ironically the strongest human evidence for anything in GLOW is topical GHK-Cu: Leyden’s randomised 12-week study in around 70 women with photoaged skin (published only as a 2002 conference abstract) beat vehicle control on skin density, thickness, laxity and fine lines. A separate 12-week study (Abdulghani 1998) took biopsies and found improved collagen production in 70% of women on GHK-Cu, versus 50% on vitamin C and 40% on retinoic acid. If skin is your goal, a properly formulated cosmetic copper-peptide serum is cheaper, better evidenced and lower risk than injecting.

Real incidence numbers exist only for single agents given intravenously, never for this blend or this route. Recombinant human thymosin β4, phase 1, 54 healthy volunteers at 0.05–25 mcg/kg IV: adverse events were mild to moderate in intensity, with no dose-limiting toxicities and no serious adverse events; no incidence rate was ever published, so anyone quoting you a percentage from that trial is making it up. An earlier Tβ4 phase 1 at 42–1260 mg IV over 14 days found headache and upper respiratory infection most common, again with no dose-limiting toxicity. BPC-157’s human record is three small uncontrolled pilot studies totalling fewer than 30 subjects: a 2025 IV safety pilot in two adults given 10 mg then 20 mg (no side effects, no measurable change in cardiac, hepatic, renal, thyroid or glucose markers), a 2021 retrospective chart review of intra-articular injection in 17 knee-pain patients, and a 2024 pilot in 12 patients with interstitial cystitis. None is randomised, none is controlled, and none uses daily subcutaneous dosing. That is an evidence gap, not a clean bill of health, and the injection-site incidence figures you will see quoted online (15–25%) come from blogs, not from any study.

Common practice is 4–6 weeks on and 2–4 weeks off, sometimes 6–8 weeks for recovery-focused runs. No human study has followed any of these three compounds past 12 weeks by any route, so continuous use is simply unstudied territory. The reason usually given for cycling (preventing receptor desensitisation) has no supporting data behind it and does not really apply to how these peptides work. The defensible reason to take off-weeks is the copper: repeated parenteral GHK-Cu accumulates exposure your gut never gets to moderate, and off-weeks cap that. If you are running back-to-back cycles for months, get serum copper and ceruloplasmin checked.

Under WADA rules, yes: both are directly targeted. BPC-157 has been prohibited under S0 (non-approved substances) since January 2022; TB-500 and thymosin β4 derivatives under S2.3 (growth factors and growth factor modulators) since 2018. Both are banned in and out of competition and are non-specified substances, meaning no reduced sanction for an accidental positive. Enforcement can also be non-analytical: possession, an order confirmation or an admission is enough to bring a case with no positive sample at all, and a four-year ineligibility has already been handed down for BPC-157 plus TB-500 together. Standard workplace and military panels do not screen for these, but military policy separately prohibits them.